TCGA-A8-A093-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- UV_RESPONSE_DN+0.290
- ESTROGEN_RESPONSE_EARLY+0.260
- PROTEIN_SECRETION+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.180
- TGF_BETA_SIGNALING+0.170
- HEME_METABOLISM+0.140
- NOTCH_SIGNALING+0.140
- MITOTIC_SPINDLE+0.120
- ADIPOGENESIS+0.110
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.570
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.530
- TNFA_SIGNALING_VIA_NFKB-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.460
- COMPLEMENT-0.340
- E2F_TARGETS-0.340
- KRAS_SIGNALING_UP-0.330
- MTORC1_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A3M8-01A-11R-A213-07 | — | B | 0.844 |
| 2 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.820 |
| 3 | SRR35579826 | — | B | 0.816 |
| 4 | SRR25617895 | — | B | 0.815 |
| 5 | 20030017.LumA | — | B | 0.814 |
| 6 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.810 |
| 7 | TCGA-B6-A0RN-01A-12R-A084-07 | — | B | 0.790 |
| 8 | SRR29022834 | — | A | 0.780 |
| 9 | TCGA-B6-A0I8-01A-11R-A034-07 | — | B | 0.780 |
| 10 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |